NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 14 full-time employees. The company went IPO on 2007-10-26. The firm manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Follow-Up Questions
Who is the CEO of NovaBay Pharmaceuticals Inc?
Mr. Justin Hall is the Chief Executive Officer of NovaBay Pharmaceuticals Inc, joining the firm since 2015.
What is the price performance of NBY stock?
The current price of NBY is $1.04, it has decreased 0% in the last trading day.
What are the primary business themes or industries for NovaBay Pharmaceuticals Inc?
NovaBay Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is NovaBay Pharmaceuticals Inc market cap?
NovaBay Pharmaceuticals Inc's current market cap is $6.0M
Is NovaBay Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 2 analysts have made analyst ratings for NovaBay Pharmaceuticals Inc, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
